FindMyKOL
Clinical trialNCT02533323TerminatedPhase 2Interventional

P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens

SponsorSun Yat-sen UniversityEnrollment50Lymphoma, Extranodal NK-T-Cell
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This prospective study was conducted to evaluate the efficacy and safety profiles of first-line combined gemcitabine, oxaliplatin, and Pegaspargase (P-Gemox) in newly diagnosed, nasal type, extranodal natural killer/T-cell lymphoma.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • yue lu, MD.

    Department of Hematological Oncology, Sun Yat-sen University Cancer Center

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Sun Yat-Sen University Cancer Center

    Guangzhou, Guangdong, China

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jan 2012
Primary completion
30 Sept 2016
Completion
31 Jan 2017
Last update posted
9 May 2018
Registered enrollment
50
Registry id
NCT02533323

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.